Evidence map›Paper›PMID 30283976›Full record

ReviewCellular and molecular life sciences : CMLS2019

Potential application of cell reprogramming techniques for cancer research.

Shigeo Saito, Ying-Chu Lin, Yukio Nakamura, Richard Eckner, Kenly Wuputra, Kung-Kai Kuo, Chang-Shen Lin, Kazunari K Yokoyama

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cellular and molecular life sciences : CMLS, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Computational Network Analysis for Defining Transcriptional Programs.Methods in molecular biology (Clifton, N.J.) · 2027
    Article
  2. Article
  3. Article
  4. Review
  5. Can the reprogrammed cancer cells serve as an alternative source of (induced) cancer stem cells?Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2024
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Generation of Induced Pluripotent Stem Cells from Patients with Multiple MyelomaTurkish journal of haematology : official journal of Turkish Society of Haematology · 2021
    Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shigeo SaitoSaito Laboratory of Cell Technology, Yaita, Tochigi, 329-1571, Japan.
Ying-Chu LinSchool of Dentistry, College of Dental Medicine, Kaohsiung Medical University, Kaohsiung, 807, Taiwan.
Yukio NakamuraCell Engineering Division, RIKEN BioResource Center, Tsukuba, Ibaraki, 305-0074, Japan.
Richard EcknerDepartment of Biochemistry and Molecular Biology, Rutgers, New Jersey Medical School-Rutgers, The State University of New Jersey, Newark, NJ, 07101, USA.
Kenly WuputraGraduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 807, Taiwan.
Kung-Kai KuoDepartment of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, 807, Taiwan.
Chang-Shen LinGraduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 807, Taiwan. changshen.lin@gmail.com.ORCID http://orcid.org/0000-0001-7415-2187
Kazunari K YokoyamaGraduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 807, Taiwan. kazu@kmu.edu.tw.ORCID http://orcid.org/0000-0001-8508-7587

Funding

Ministry of Science and Technology, Taiwan MOST-106-2314-B-037-017The National Health Research Institutes NHRI-Ex107-10720SI
6 · The paper itself

Abstract

The ability to control the transition from an undifferentiated stem cell to a specific cell fate is one of the key techniques that are required for the application of interventional technologies to regenerative medicine and the treatment of tumors and metastases and of neurodegenerative diseases. Reprogramming technologies, which include somatic cell nuclear transfer, induced pluripotent stem cells, and the direct reprogramming of specific cell lineages, have the potential to alter cell plasticity in translational medicine for cancer treatment. The characterization of cancer stem cells (CSCs), the identification of oncogene and tumor suppressor genes for CSCs, and the epigenetic study of CSCs and their microenvironments are important topics. This review summarizes the application of cell reprogramming technologies to cancer modeling and treatment and discusses possible obstacles, such as genetic and epigenetic alterations in cancer cells, as well as the strategies that can be used to overcome these obstacles to cancer research.

Indexed as

Cellular ReprogrammingAnimalsCellular Reprogramming TechniquesEpigenesis, GeneticGene Expression Regulation, NeoplasticHumansNeoplasmsNeoplastic Stem CellsTumor MicroenvironmentCancer stem cellsEpigeneticsInduced pluripotent stem cellsOrganoid cultureReactive oxygen speciesSomatic cell nuclear transfer

Identifiers

PMID30283976
PMCPMC6326983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.